CD274 and neoplasm: In recent years, a variety of biomarkers have been investigated to reflect the effects of ICIs, including PD-L1 expression in tumor cells, the tumor mutation burden, the neoantigen burden, polybromo1 gene mutation, immune cell infiltration, and the gut microbiota.